Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial.
A 4-week, double-blind, placebo-controlled trial of amantadine was conducted in 61 cocaine dependent outpatients. Subjects received 100 mg of amantadine 3 times daily. A follow-up visit was conducted at week 8. There were no significant differences between groups in treatment retention, or in the number of benzoylecgonine positive urine samples. Self-reported drug and alcohol use declined in both groups. At week 8 follow-up, self-reported drug use was significantly lower in the placebo group. Amantadine was not effective, and discontinuation of it may have been associated with an increase in cocaine use.
Kampman
K
K
University of Pennsylvania Treatment Research Center, Philadelphia 19104, USA.
Volpicelli
J R
JR
Alterman
A
A
Cornish
J
J
Weinrieb
R
R
Epperson
L
L
Sparkman
T
T
O'Brien
C P
CP
D000328:Adult; D000437:Alcoholism / Q000175:diagnosis / Q000523:psychology / Q000534:rehabilitation; D000547:Amantadine / Q000627:therapeutic use*; D003042:Cocaine; D015897:Comorbidity; D015259:Dopamine Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009293:Opioid-Related Disorders / Q000175:diagnosis / Q000523:psychology / Q000534:rehabilitation*; D015813:Substance Abuse Detection; D016896:Treatment Outcome
D015259:Dopamine Agents; D000547:Amantadine; D003042:Cocaine